These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 15383187)

  • 61. Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
    Jayaram S; Prasad HB; Sovani VB; Langade DG; Mane PR
    J Indian Med Assoc; 2007 Mar; 105(3):142-5, 150. PubMed ID: 17824470
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Mercouris BR; Pehlivanidis A; Bouloukos VI; Elisaf M;
    Curr Med Res Opin; 2004 May; 20(5):627-37. PubMed ID: 15171226
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study.
    Neil HA; Fowler G; Patel H; Eminton Z; Maton S
    Int J Clin Pract; 1999 Sep; 53(6):422-6. PubMed ID: 10622068
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.
    Leiter LA; Bays H; Conard S; Lin J; Hanson ME; Shah A; Tershakovec AM
    Int J Clin Pract; 2010 Dec; 64(13):1765-72. PubMed ID: 20946261
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of dyslipidaemia in high-risk patients: too little, too late.
    Barter P
    Int J Clin Pract Suppl; 2002 Jul; (130):15-9. PubMed ID: 12296602
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(8):499-502. PubMed ID: 12564661
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S; Malhotra S; Sharma YP; Pandhi P
    J Cardiovasc Pharmacol; 2012 May; 59(5):479-84. PubMed ID: 22569288
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.